Low-density lipoprotein and ritonavir: An interaction between antiretrovirals and lipids mediated by P-glycoprotein

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1760-1766

  Tempestilli, Massimo ^a   Elisei, Federica ^a   Cimini, Eleonora ^a   D'avolio, Antonio ^b   Grassi, Germana ^a   Nicastri, Emanuele ^a   Narciso, Pasquale ^a   Martini, Federico ^a   Alonzi, Tonino ^a   Paolo Pucillo, Leopoldo ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Multidrug resistance; Protease inhibitors; THP 1

Indexed keywords

FILIPIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; RITONAVIR; VERAPAMIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOW DENSITY LIPOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BINDING;

ARTICLE; CELL MEMBRANE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG ACCUMULATION; FLOW CYTOMETRY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPID HOMEOSTASIS; MOLECULAR INTERACTION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; CELL LINE; CHEMISTRY; CYTOSOL; GENE EXPRESSION PROFILING; METABOLISM; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTI-HIV AGENTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LIPOPROTEINS, LDL; MONOCYTES; P-GLYCOPROTEIN; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; RITONAVIR; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84902491073     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku066     Document Type: Article

References (43)

1. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EUROSIDA study: an observational study. Lancet 2003; 362: 22-9.
2. Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105: 3879-84.
3. Giannarelli C, Klein RS, Badimon JJ. Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis 2011; 219: 384-9.
4. Vittecoq D, Escaut L, Merad M et al. Coronary heart disease in HIV-infected individuals. Adv Cardiol 2003; 40: 151-62.
5. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-74.
6. Friis-Møller N, Sabin CA, Weber R et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2004; 350: 1993-2003.
7. DAD Study Group, Friis-Møller N, Reiss P et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
8. McKeegan KS, Borges-Walmsley MI, Walmsley AR. The structure and function of drug pumps: an update. Trends Microbiol 2003; 11: 21-9.
9. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
10. Sankatsing SU, Beijnen JH, Schinkel AH et al. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48: 1073-81.
11. Janneh O, Jones E, Chandler B et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-93.
12. Meaden ER, Hoggard PG, Newton P et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50: 583-8.
13. Tempestilli M, Gentilotti E, Tommasi C et al. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors. Int Immunopharmacol 2013; 16: 492-7.
14. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273: 32380-3.
15. Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem Sci 2000; 25: 530-4.
16. Eckford PD, Sharom FJ. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 2008; 47: 13686-98.
17. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 2002; 99: 10347-52.
18. Troost J, Albermann N, Emil Haefeli W et al. Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2004; 316: 705-11.
19. Aye IL, Singh AT, Keelan JA. Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. Chem Biol Interact 2009; 180: 327-39.
20. Banka CL, Black AS, Dyer CA et al. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J Lipid Res 1991; 32: 35-43.
21. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of RTV-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 4-9.
22. Baumert C, Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 2009; 9: 415-36.
23. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30: 1360-9.
24. Norman AW, Demel RA, de Kruyff B et al. Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J Biol Chem 1972; 247: 1918-29.
25. Beck WT, Grogan TM, Willman CL et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-20.
26. Meaden ER, Hoggard PG, Khoo SH et al. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262: 159-65.
27. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
28. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
29. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7: 787-96.
30. Anastos K, Lu D, Shi Q et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007; 45: 34-42.
31. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant tomultiple protease inhibitors. Nature 1995; 374: 569-71.
32. Hoetelmans RMW. Sanctuary sites in HIV-1 infection. Antiviral Ther 1998; 3: 13-7.
33. Troost J, Lindenmaier H, Haefeli WE et al. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 2004; 66: 1332-9.
34. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999; 259: 18-24.
35. Rothnie AD, Theron L, Soceneantu C et al. The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur Biophys J 2001; 30: 430-42.
36. Funaki S, Takahashi S, Wada N et al. Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome. Pediatr Int 2008; 50: 159-61.
37. Ueda S, Sugimoto K, Yanagida H et al. Low-density lipoprotein adsorption therapy can restore drug sensitivity for immunosuppressants via inhibitory effects upon MDR-1 gene expression. Ther Apher Dial 2011; 15: 499-503.
38. Muso E, Mune M, Yorioka N et al. Beneficial effect of lowdensity lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007; 67: 341-4.
39. Ansermot N, Rebsamen M, Chabert J et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab Lett 2008; 2: 76-82.
40. Takahashi K, Kimura Y, Nagata K et al. ABC proteins: key molecules for lipid homeostasis. Med Mol Morphol 2005; 38: 2-12.
41. Wang X, Mu H, Chai H et al. Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophagederived foam cells. Am J Pathol 2007; 171: 304-14.
42. Dressman J, Kincer J, Matveev SVet al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111: 389-97.
43. D'Avolio A, Simiele M, Calcagno A et al. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J Antimicrob Chemother 2013; 68: 907-10.